Geert‐Jan Creemers

Author

Geert‐Jan Creemers

Also Known As

Creemers, Geert-Jan, Esther C.J. Consten, G. Creemers, Geert-Jan Creemers, Geert-jan Creemers, Geert‐Jan Creemers, Geert‐Jan M. Creemers, Lodewijk A. A. Brosens, Marien O. den Boer

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Catharina Ziekenhuis University Medical Center Utrecht Erasmus MC Netherlands Comprehensive Cancer Organisation

About

Geert‐Jan Creemers is an author at Radboud University Nijmegen specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.7K
2	Health Sciences	4	4	709
3	Gastroenterology	4	4	939
4	Public Health	2	2	83
5	Health Informatics	1	1	36

Geert‐Jan Creemers

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken, The Lancet Oncology Surgical OncologyChemotherapy Versus ChemoradiotherapyGastrointestinal OncologyResectable Gastric CancerMedicine	2018	562
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study Bo Jan Noordman, Manon C.W. Spaander, Roelf Valkema, The Lancet Oncology Residual DiseaseSurgical OncologyEsophageal CancerGastrointestinal OncologyMedicine	2018	320
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial Charlotte E.L. Klaver, D D Wisselink, Cornelis J.A. Punt, The Lancet. Gastroenterology & hepatology Health SciencesGastrointestinal OncologyMedicineRandomised TrialClinical Trials	2019	312
Clinical management of women with metastatic breast cancer: a descriptive study according to age group Klaartje Manders, Lonneke V. van de Poll‐Franse, Geert‐Jan Creemers, BMC Cancer	2006	142
The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis Tara M. Mackay, F. Jasmijn Smits, Daphne Roos, HPB Nationwide AnalysisSurgical OncologyPancreatic CancerGastrointestinal OncologyMedicine	2019	111
Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre M. Bontenbal, Geert‐Jan Creemers, Hans J. Braun, Journal of Clinical Oncology	2005	102
Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients Sophie A. Kurk, Petra H.M. Peeters, Rebecca K. Stellato, Journal of Cachexia Sarcopenia and Muscle	2019	101
Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for <b> <i>UGT1A1*28</i> </b> Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled Study Floris A. de Jong, Diederik F.S. Kehrer, Ron H.J. Mathijssen, The Oncologist	2006	88
The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population‐based analysis Maikel J. A. M. Bakens, Lydia G. van der Geest, Magreet van Putten, Cancer Medicine	2016	80
Patterns of local recurrence in locally advanced rectal cancer after intra-operative radiotherapy containing multimodality treatment Miranda Kusters, Fabian A. Holman, Hendrik Martijn, Radiotherapy and Oncology Adaptive RadiotherapyNeuro-oncologyIntra-operative RadiotherapyRadiation TherapyMedicine	2009	61

Page 1